Full Year 2023 Investor Presentation
136
Investor presentation
Full year 2023
North America Operations at a glance.
NAO
Diabetes trend in population
Diabetes market by value and
Novo Nordisk market share
Novo Nordisk reported sales
589
Million
70
10%
60
11%
900
DKK
MS
Full year 2023
billion
Sales
(MDKK)
Growth²
Injectable GLP-13
73,154
54%
80%
RybelsusⓇ
11,361
43%
50
Total GLP-1
84,515
52%
60%
4320
40
600
Total insulin4
10,792
-23%
GLP-1
Other Diabetes care5
325
-30%
30
63
57
40%
46.0%¹
51
Diabetes care
95,632
36%
20
10
300
0.5%¹
Insulin
Obesity care
33,317
212%
20%
Diabetes & Obesity
OAD
128,949
60%
17.3%1
care
0
2021
0
0%
Nov
2030
2045
2018
Nov
2023
Rare disease?
Total
7,680
136,629
-1%
54%
Population with diabetes
Diabetes growth rate
GLP-1 MS
-Insulin MS
-OAD MS
International Diabetes Federation: Diabetes Atlas 1th Edition
2000 and Diabetes Atlas 10th Edition 2021
1 CAGR calculated for 5-year period
Competitor insulin value market shares, as of Nov 2023: Novo Nordisk 42%,
Others 58%; Competitor GLP-1 value market shares, as of Nov 2023: Novo
Nordisk 53%, Others 47%. OAD: Oral anti-diabetic; MS: Market Share; Note:
Market values are based on list prices; Source: IQVIA MAT, Nov 2023 value
figures
2 At constant exchange rates; ³ Comprises VictozaⓇ, Ozempic®;
4 Comprises Tresiba®, XultophyⓇ, Levemir®, NovoMix®, Fiasp® and NovoRapidⓇ;
5Comprises Novo NormⓇ and needles; 6 Comprises SaxendaⓇ and WegovyⓇ
7Comprises primarily NovoSeven®, Novo Eight® Esperoct®, NovoThirteen®,
Refixia®, Norditropin®, Vagifem® and ActivelleⓇView entire presentation